Additionally, PD-L1 carried by EVs is thought to act as a biomarker for a number of tumour types, showing the capacity to be used to predict disease activity and tumour development and evaluate responses to immunotherapy [143–145]. The gene discussed is CD274; the disease is neoplasm.